Ozempic and Wegovy Linked to 40% Fewer Asthma Attacks in Large Study
Semaglutide, the active pharmaceutical ingredient found in the type 2 diabetes and weight-loss medications Ozempic and Wegovy, is linked to nearly 40 percent fewer asthma attacks in a large real-world study presented at the European Respiratory Society Congress in Barcelona, Spain. Researchers from Imperial College London analyzed UK electronic health records to evaluate respiratory outcomes among patients managing chronic airway diseases, finding that glucagon-like peptide-1 (GLP-1) receptor agonists may offer substantial pulmonary benefits beyond glycemic control and metabolic management.
- A real-world study presented at the European Respiratory Society Congress tracked adults with asthma and chronic obstructive pulmonary disease in the UK.
- Patients prescribed semaglutide experienced nearly a 40 percent reduction in acute asthma attacks compared to individuals taking older diabetes therapies like sulfonylureas.
- Investigators, including lead researcher Chloe Bloom, emphasize that clinical trials are required before these medications can be formally indicated for respiratory conditions.
Real-World Data and Study Design
The observational investigation, led by Professor Chloe Bloom of the National Heart and Lung Institute at Imperial College London and presented by Dr. Bohee Lee, evaluated UK electronic medical records across four parallel cohorts. Each arm of the study examined between 20,000 and 22,000 adults who had newly initiated treatment with either a GLP-1 receptor agonist or a sulfonylurea while managing pre-existing asthma or chronic obstructive pulmonary disease (COPD). According to the findings, acute respiratory attacks—defined in the dataset as short courses of oral corticosteroids, emergency room visits, hospitalizations, or death—occurred less frequently among patients taking GLP-1 medications. Across the drug class, exacerbations were about 14 percent lower than in comparator groups, with semaglutide demonstrating the most pronounced clinical association.
Professor Bloom noted that while GLP-1 receptor agonists are widely prescribed for type 2 diabetes and obesity due to their mechanisms in slowing gastric emptying and reducing appetite, traditional clinical trials for these drugs have not typically tracked asthma or COPD metrics as primary endpoints.
Evaluating Biological Mechanisms and Clinical Caution
Obesity and metabolic dysfunction frequently intersect with airway diseases, with asthma incidence rising by approximately 50 percent in individuals who are overweight or obese. Prior research indicates that GLP-1 receptor agonists suppress systemic inflammation, evidenced by reductions in high-sensitivity C-reactive protein levels. Furthermore, a post-hoc analysis of Novo Nordisk’s SELECT trial identified fewer asthma-related adverse events among patients randomized to semaglutide compared to placebo, yielding a hazard ratio of 0.58, though that trial was not originally designed as an evaluation of pulmonary efficacy.
Despite the encouraging statistical associations observed in observational health records, lead investigators urge strict adherence to current prescribing guidelines. Professor Bloom cautioned that the data should not alter clinical practice independently. People with asthma or COPD should not seek out semaglutide specifically to treat their lung conditions outside established indications until the findings gain robust validation in randomized, controlled clinical trials. Dr. Alexander Mathioudakis of the University of Manchester, who was not involved in the research, noted that while the study represents one of the largest real-world evaluations of GLP-1 therapies in airway diseases, future metabolic trials must explicitly incorporate respiratory endpoints to establish causality.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.